Jazz pays $125m upfront for sleep drug

Jazz Pharmaceuticals has followed up its $1bn December acquisition of Italian company Gentium with a new agreement to buy rights to Aerial BioPharma's ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Jazz is paying $125m upfront for the product.

Jazz Pharmaceuticals has followed up its $1bn December acquisition of Italian company Gentium with a new agreement to buy rights to Aerial BioPharma's ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Jazz is paying $125m upfront for the product.

Investors liked the deal: Jazz shares closed 6% up at $146.84 on the news (13 January 2014).

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category